2/10
07:14 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Guggenheim.
2/9
04:01 pm
prax
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
Low
Report
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
2/8
03:36 am
prax
A Look At Praxis Precision Medicines (PRAX) Valuation As Analysts Reaffirm Bullish CNS Pipeline Views [Yahoo! Finance]
Low
Report
A Look At Praxis Precision Medicines (PRAX) Valuation As Analysts Reaffirm Bullish CNS Pipeline Views [Yahoo! Finance]
2/4
04:01 pm
prax
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/4
08:03 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Needham & Company LLC from $460.00 to $510.00. They now have a "buy" rating on the stock.
Medium
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Needham & Company LLC from $460.00 to $510.00. They now have a "buy" rating on the stock.
2/2
10:26 am
prax
SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders [Yahoo! Finance]
Low
Report
SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders [Yahoo! Finance]
2/2
07:00 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) is now covered by analysts at Wells Fargo & Company. They set an "equal weight" rating and a $282.00 price target on the stock.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) is now covered by analysts at Wells Fargo & Company. They set an "equal weight" rating and a $282.00 price target on the stock.
1/30
07:17 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/29
10:59 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at TD Cowen.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at TD Cowen.
1/29
07:43 am
prax
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar? [Yahoo! Finance]
Low
Report
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar? [Yahoo! Finance]
1/28
07:03 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/15
11:52 am
prax
Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus [Yahoo! Finance]
Low
Report
Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus [Yahoo! Finance]
1/14
04:31 am
prax
Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge? [Yahoo! Finance]
Medium
Report
Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge? [Yahoo! Finance]
1/13
04:30 pm
prax
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
Medium
Report
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
1/12
09:02 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Wedbush from $83.00 to $95.00. They now have an "underperform" rating on the stock.
Medium
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Wedbush from $83.00 to $95.00. They now have an "underperform" rating on the stock.
1/12
08:27 am
prax
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress [Yahoo! Finance]
Medium
Report
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress [Yahoo! Finance]
1/12
08:00 am
prax
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
Medium
Report
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
1/11
01:26 am
prax
Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX) [Yahoo! Finance]
Medium
Report
Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX) [Yahoo! Finance]
1/9
04:01 pm
prax
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/8
04:45 pm
prax
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
Low
Report
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
1/7
01:33 pm
prax
Praxis Precision Medicines (PRAX) Valuation Check After A Strong 90 Day Share Price Run [Yahoo! Finance]
Low
Report
Praxis Precision Medicines (PRAX) Valuation Check After A Strong 90 Day Share Price Run [Yahoo! Finance]
1/6
11:15 pm
prax
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
Medium
Report
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
1/6
04:03 pm
prax
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
High
Report
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
1/5
08:42 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
1/2
02:01 pm
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Cowen Inc.